Abu dhabi: The Emirates Drug Establishment (EDE) has officially granted approval for EURneffy, a novel epinephrine-based treatment available in 1 mg and 2 mg strengths, making the UAE the first country in the region to authorise this innovative therapy.
According to Emirates News Agency, this marks a significant development in the healthcare and pharmaceutical landscape of the UAE, as EURneffy introduces the first nasal adrenaline spray indicated for the emergency treatment of severe allergic reactions in adults and children aged four years and above.
Developed by ALK Abell³, the product enables the administration of epinephrine via the nasal route as an alternative to injections. This advancement supports faster responses in acute allergic emergencies, where timely administration of epinephrine is critical to saving lives. It also addresses practical challenges associated with injectable treatments, including hesitation due to needle-related anxiety and difficulties in administration during critical moments.
EURneffy is designed for ease of use and rapid administration, enabling immediate intervention even by non-medically trained individuals. Its simplicity reduces hesitation and accelerates response at the onset of symptoms, thereby improving survival outcomes and overall patient safety. The Emirates Drug Establishment was first introduced to this innovation during a recent visit to Denmark and worked closely with the manufacturer to accelerate its availability to patients in the UAE.
EURneffy's approval is part of EDE's ongoing efforts to strengthen healthcare system readiness and expand access to innovative treatment options. Dr Fatima Al Kaabi, Director General of the Emirates Drug Establishment, emphasized the UAE's strategic direction to adopt innovative therapies that have a direct impact on patients' lives. Al Kaabi highlighted the priority of providing advanced and easy-to-use treatment options in critical situations to improve response rates and reduce risks associated with delayed intervention.
Ghassan Al Qatib, Regional General Manager at ALK Abell³, stated that the approval of EURneffy is an important step towards improving access for patients and healthcare providers to effective and easy-to-use treatment options in emergency situations. Al Qatib expressed commitment to delivering innovative therapies in collaboration with partners, reflecting a shared commitment to advancing pharmaceutical care in the UAE and across the region.
With this approval, the UAE reinforces its position as a hub for medical innovation, supported by a flexible regulatory framework that ensures rapid access to advanced therapies while maintaining the highest standards of quality and safety.